Payers provide insights to health care disparities currently impacting patients with major depressive disorder (MDD).
Jay Weaver, PharmD, MPH: When we’ve looked at health equity and disparities in care within our plan along the lines of major depression and other psychological illnesses, we see that there are some ethnic groups less likely to seek services or less likely to know about services available to them. There’s a health education gap within our populations. Some of our more aged populations are less likely to utilize some of our remote care. That’s challenging because within our markets we have a shortage of health care providers who provide counseling and other services, such that bridging that with virtual care is important to make sure we have plenty of providers available at a very short notice. The other thing we’ve noticed is that certain ethnic groups may not be willing to seek psychiatric services. There might be stigmas in care that folks perceive around seeking care for depression.
Mona Chitre, PharmD, CGP: There are health care disparities in major depressive disorder. We absolutely see them come through in our data as well as in national publications. One in every 2 American adults will be affected by a mental health event, whether it’s acute or chronic. However, the burden is disproportionate in our underserved populations, mostly our Black and brown populations. This can be because of implicit and explicit bias. It can be because of lack of access to good-quality care. It can be because of a host of social determinants of health. But health care disparities are a trigger for mental health disorders as well as major depressive disorder.
Transcript edited for clarity.
MINT Trial 26-Week Data Show Inebilizumab for gMG Is Effective and Safe
April 1st 2025These are data to week 26 on the monoclonal antibody and antineoplastic agent; data out to week 52 of the MINT trial will be presented in a late-breaking oral session at the upcoming American Academy of Neurology Annual Meeting.
Read More
FDA Approves Cabozantinib for Advanced Pancreatic Neuroendocrine Tumors
March 26th 2025With strong progression-free survival benefits demonstrated in the CABINET trial and updates to National Comprehensive Cancer Network guidelines, this approval reinforces cabozantinib’s role in improving outcomes for patients facing these challenging cancers.
Read More
PAH Therapies Improve Outcomes in PH-ILD
March 26th 2025Pulmonary hypertension is a common consequence of interstitial lung disease (PH-ILD), with the highest rate seen among individuals who have idiopathic pulmonary fibrosis. Overall, most cases of PH in the setting of ILD are mild.
Read More